Pluviaendo Visuals Pluviaendo Visuals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Brandon Capital","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brandon Capital Co-Leads USD 68M Series A Financing of London-Based ADC Company Pheon Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Biocytogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Pharmaceuticals Enters into License Agreement with Pheon Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Pheon Therapeutics

    Menu

    Pheon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Pheon Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biocytogen Pharmaceuticals Enters into License Agreement with Pheon Therapeutics

              Details:

              Under the terms of the agreement, Pheon will develop and commercialize a next generation antibody-drug conjugate (ADC) for a wide range of hard-to-treat cancers developed using Biocytogen’s proprietary RenMiceTM platforms.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Recipient: Biocytogen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pheon Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Brandon Capital Co-Leads USD 68M Series A Financing of London-Based ADC Company Pheon Therapeutics

              Details:

              The investment will enable Pheon to advance its lead ADC program PHN-010, to clinical proof-of-concept and establish a pipeline of novel ADCs. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors.

              Lead Product(s): PHN-010

              Therapeutic Area: Oncology Product Name: PHN-010

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Brandon Capital

              Deal Size: $68.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing September 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
              Axplora- The partner of choice for complex APIs.
              Post Enquiry
              POST ENQUIRY